Related Experiment Videos
[Chemotherapy for advanced pancreatic carcinoma]
1Department of Internal Medicine, National Cancer Center Hospital, Tokyo, Japan.
Gan to Kagaku Ryoho. Cancer & Chemotherapy
|December 1, 1992
Summary
Chemotherapy for advanced pancreatic cancer offers limited palliative benefits, lacking a standard regimen for improved survival or response rates. New drugs or combination therapies are needed for better patient outcomes.
Area of Science:
- Oncology
- Medical Chemistry
Context:
- Advanced pancreatic cancer lacks curative chemotherapy options.
- Current chemotherapy aims to palliate symptoms and improve patient quality of life.
- No single chemotherapeutic regimen demonstrates a clear survival or response rate advantage.
Purpose:
- To review current chemotherapy approaches for advanced pancreatic cancer.
- To highlight challenges in assessing treatment response.
- To identify areas for future therapeutic development.
Summary:
- Single-agent chemotherapy involves drugs like 5-fluorouracil (5-FU) and mitomycin C (MMC), with others like streptozotocin and cisplatin (CDDP) under investigation.
- Combination regimens such as FAM and SMF have been used, with FP and biochemical modulation recently gaining attention.
- Accurate response rate determination is hindered by methodological difficulties.
Impact:
- Highlights the unmet need for more effective treatments in advanced pancreatic cancer.
- Emphasizes the ongoing search for novel chemotherapeutic agents and combination strategies.
- Suggests that future research should focus on new drugs or combined modality approaches for improved patient outcomes.